Article Text

Download PDFPDF

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
  1. Gulidanna Shayan1 and
  2. Robert L Ferris2
  1. Aff1 grid.21925.3d0000000419369000University of Pittsburgh Hillman Cancer Center Pittsburgh PA USA
  2. Aff2 grid.21925.3d0000000419369000University of Pittsburgh Cancer Institute Pittsburgh PA USA

Statistics from Altmetric.com

Meeting abstracts

Programmed Death 1 (PD-1) and T cell Ig and mucin domain-3 protein (Tim-3) are immune check point receptors that are upregulated on tumor infiltrating lymphocytes (TIL) in tumor-bearing mice and humans. As anti-PD-1 single agent response rates are still relatively low (20%) in HNC patients, it is important to learn how different inhibitory check point receptors work together to maintain the suppressive status of immune system. We observed that PD-1 and Tim-3 co-expression is associated with an exhausted phenotype of HNSCC TIL of patients, demonstrating the highest PD-1 levels in Tim-3 double positive TIL. We also observed that PD-1+/Tim-3+ TIL manifest dampened in Akt/p-S6 activation upon TCR stimulation, leading us to infer the potential for signaling cross-talk between PD-1 and Tim-3 downstream signaling pathways. Indeed, in freshly isolated HNSCC TIL, PD-1-/TIM-3+ T cells showed higher baseline expression of p-SHP-2 (p < 0.01) which is triggered upon PD-1 ligation. In addition, PD-1 blockade using nivolumab of human HNSCC TIL led to upregulation of Tim-3 expression, suggesting a circuit of compensatory, cross-talk signaling and permitting escape from anti-PD-1 blockade during TCR stimulation. In a murine HNC tumor model, anti-PD-1 treatment modestly suppressed tumor growth, but in TIL from persistent tumors in these mice, Tim-3 expression was dramatically upregulated after PD-1 blockade. Taken together, in response to PD-1 blockade, the most exhausted TIL appear to upregulate Tim-3 as a compensatory mechanism, supporting dual targeting, which may provide new therapeutic strategy for cancer immunotherapy.

Figure1

Figure 1

Figure2

Figure 2

Figure3

Figure 3

Figure4

Figure 4

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.